---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-032135"
form_type: "8-K"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2025-04-15T23:59:59+00:00"
generated_at: "2026-05-23T14:14:00.796925+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ABVC BioPharma reports 2024 revenue up 234%, EPS improves 77%, but restates FY2023 financials

## Summary
- Revenue $509,589 (+234% YoY); net loss narrowed to $4.90M; EPS improved 77% to ($0.42).
- Operating expenses cut 21% to $5.21M; SG&A down 58%, R&D down 83%.
- Remaining milestone payments potential of $18.3M from licensing partners.
- Board concludes FY2023 financials should no longer be relied upon due to errors in share-based payments, interest, non-controlling interest.
- Material weakness in internal controls over financial reporting identified.

## SEC filing metadata
- accession: 0001213900-25-032135
- form_type: 8-K
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2025-04-15T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 4.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390025032135/0001213900-25-032135-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390025032135/ea0238372-8k_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-032135
- JSON: https://secwatch.observer/filing/0001213900-25-032135.json
- Plain text: https://secwatch.observer/filing/0001213900-25-032135.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.